

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

**(1) DELAY IN DESPATCH OF CIRCULAR IN RELATION TO
VERY SUBSTANTIAL ACQUISITION AND
CONNECTED TRANSACTION INVOLVING THE ISSUE OF
CONSIDERATION SHARES UNDER SPECIFIC MANDATE AND
PROPOSED SHARE CONSOLIDATION**
**(2) DELAY IN TIMETABLE IN RELATION
TO PROPOSED SHARE CONSOLIDATION AND
PROPOSED CHANGE IN BOARD LOT SIZE**

Reference is made to the announcement of Kaisa Health Group Holdings Limited (the “**Company**”) dated 18 March 2026 (the “**Announcement**”) in relation to, among others, a very substantial acquisition and connected transaction, a share consolidation and change in board lot size. Capitalised terms used herein shall have the same meanings as those defined in the Announcement, unless the context requires otherwise.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, (i) further details of the Acquisition; (ii) a letter of recommendation of the Independent Board Committee in relation to the Acquisition; (iii) a letter of advice from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders in relation to the Acquisition; (iv) the audited financial information of the Target Group; (v) the unaudited pro forma financial information of the Enlarged Group upon Completion; (vi) the valuation report on the Target Company; (vii) further details of the Share Consolidation and the Change in Board Lot Size; (viii) the notice convening the SGM; and (ix) other information as required under the Listing Rules, is expected to be despatched to the Shareholders on or before 5 May 2026, as additional time is required to prepare the financial information of the Target Group and the valuation report on the Target Company to be included in the Circular.

As additional time is required for the Company to finalise certain information to be included in the Circular, it is expected that the Circular will be despatched on or before 30 June 2026.

As a result of the delay in despatch of the Circular, the expected timetable for the Share Consolidation and the Change in Board Lot Size will be delayed. The revised timetable for the proposed Share Consolidation and the proposed Change in Board Lot Size will be announced in due course.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Kaisa Health Group Holdings Limited
Kwok Ying Shing
Chairman

Hong Kong, 14 May 2026

As at the date of this announcement, the Board comprises six executive Directors, namely Mr. Kwok Ying Shing (Chairman), Mr. Luo Jun, Ms. Luo Tingting, Mr. Liu Lihao, Mr. Xie Binhong and Mr. Ye Haoda and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping and Ms. Li Zhiying.